drugset / Trial / NCT03175549
Medication Development in Alcoholism: Apremilast Versus Placebo
Phase 2
Completed
51 enrolled
The Scripps Research Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA) · collab
RandomizedParallel-groupQuadruple-blindOther
Summary
The primary hypotheses under test are that alcohol dependent subjects treated with apremilast will report decreased craving for alcohol following alcohol exposure in the laboratory and report significantly less drinking under naturalistic conditions, than those treated with placebo.
Timeline
- Start
- 2017-11-01
- Primary completion
- 2020-04-01
- Completion
- 2020-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Apremilast | Small molecule | 90 mg | Oral |